Therapeutics Pipeline

Our pipeline includes innovative, high-impact programs that reflect our commitment to translating cutting-edge science into meaningful therapeutic advances. In addition to those shown above, we have multiple assets spanning a range of modalities, including small molecule inhibitors (SMIs), bispecifics, molecular glues and antibody-radionuclide conjugates (ARCs). The selections below highlight programs that exemplify some of our most differentiated concepts, spanning both emerging innovations and efforts approaching key development milestones. 

Therapeutics Discovery spearheaded the discovery and translational development of ART0380 (alnodesertib), a first‑in‑class ATR inhibitor now advancing in the clinic through our partnership with Artios Pharma. Through an intensive medicinal chemistry effort that produced more than 700 compounds, Therapeutics Discovery identified ART0380 for its superior pharmacologic profile and then built the scientific framework that defined its precision‑oncology strategy, demonstrating potent synthetic lethality in ATM‑deficient tumors and establishing biomarker‑driven patient selection. These foundational insights directly enabled the strong clinical performance now emerging from Artios’s STELLA Phase 1/2a trial, where alnodesertib combined with low‑dose irinotecan has shown compelling and durable responses across multiple hard‑to‑treat solid tumors, including a 50% confirmed response rate in ATM‑negative cancers. The FDA’s Fast Track designation for alnodesertib in third‑line ATM‑negative metastatic colorectal cancer underscores the program’s transformative potential and accelerates its path toward pivotal studies. As expansion cohorts open in earlier‑line pancreatic and colorectal cancers, Therapeutics Discovery’s discovery leadership and translational innovation continue to drive this therapy from concept to clinical impact, reinforcing UT MD Anderson’s commitment to advancing breakthrough treatments for patients with urgent unmet needs.

Therapeutics Discovery scientists at UT MD Anderson played a foundational role in the discovery and preclinical development of CBX-250, a first-in-class CG1 x CD3 T cell engager (TCE) now advancing in the clinic through our strategic collaboration with Crossbow Therapeutics. UT MD Anderson investigators led the identification and validation of CG1 (a cathepsin G-derived peptide abundantly displayed on leukemic cells by HLA-A02, but not on normal cells) using functional T cell studies and mass spectrometry analysis of patient AML and CML samples. Working through Therapeutics Discovery's protein therapies and advanced biologics platform, our scientists then developed a TCR-mimetic binder to the CG1/HLA-A02 complex — the molecular core that Crossbow licensed and engineered into CBX-250's optimized T-Bolt™ TCE format. The resulting therapy demonstrated potent and selective anti-leukemic activity in preclinical models with no meaningful activity against normal tissues, including bone marrow. In July 2025, the first patient was dosed in the CROSSCHECK-001 Phase 1 trial (NCT06994676), an open-label, dose-escalation study evaluating CBX-250 in patients 12 years and older with relapsed or refractory AML, high-risk MDS, CMML and CML — diseases with urgent unmet need and limited treatment options. Early safety and clinical activity data from this trial are anticipated as enrollment progresses, with expanded cohorts and results expected to define the path toward broader development in myeloid malignancies.

Therapeutics Discovery's glutaminase (GLS1) inhibitor program continues to advance as a leading example of our commitment to developing innovative therapies for patients with high unmet need. IACS‑6274, discovered and developed within UT MD Anderson’s Therapeutics Discovery engine, has shown encouraging early antitumor activity, durable disease control in biomarker‑defined cancers and clear evidence of on‑target GLS1 inhibition in its ongoing Phase 1 trial. These results reflect years of integrated chemistry, biology and translational research across our matrixed platforms to identify patient populations most likely to benefit, including KEAP1/NFE2L2‑mutant NSCLC, ASNS‑low ovarian cancer and tumors resistant to immune checkpoint inhibitors. In parallel, IACS‑6274 is now being evaluated in combination with bevacizumab and paclitaxel, with enrollment that is progressing toward expansion. Together, these efforts highlight Therapeutics Discovery's goal to translate deep mechanistic insight into impactful therapies and to accelerate the development of first‑in‑class treatments for underserved patient groups.